Low-level viremia early in HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 4, 2014, Pages 405-408

  Chen, Iris ^a   Cummings, Vanessa ^a   Fogel, Jessica M ^a   Marzinke, Mark A ^a   Clarke, William ^a   Connor, Matthew B ^b   Griffith, Sam ^c   Buchbinder, Susan ^d   Shoptaw, Steven ^e   Del Rio, Carlos ^f   Magnus, Manya ^g   Mannheimer, Sharon ^h   Wheeler, Darrell P ⁱ   Mayer, Kenneth H ^j   Koblin, Beryl A ^k   Eshleman, Susan H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c FAMILY HEALTH INTERNATIONAL   (United States)

^d SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f EMORY UNIVERSITY   (United States)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ LOYOLA UNIVERSITY CHICAGO   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k NEW YORK BLOOD CENTER   (United States)

more..

Author keywords

Diagnosis; HIV; HIV controllers; Seroconversion; Viral load

Indexed keywords

DARUNAVIR; EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; ENZYME IMMUNOASSAY; FALSE NEGATIVE RESULT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS LOAD; WESTERN BLOTTING; ADOLESCENT; ADULT; BLOOD; VIREMIA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84922480272     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000298     Document Type: Article

References (23)

1. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-1879.
2. Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol. 2013;13:487-498.
3. Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis. 2009;200: 1714-1723.
4. Madec Y, Boufassa F, Porter K, et al. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS. 2005;19:2001-2007.
5. Miura T, Brumme ZL, Brockman MA, et al. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol. 2010;84:7581-7591.
6. Madec Y, Boufassa F, Porter K, et al. Natural history of HIV-control since seroconversion. AIDS. 2013;27:2451-2460.
7. Centers for Disease Control and Prevention. Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm-United States, 2011-2013. MMWR Morb Mortal Wkly Rep. 2013;62:489-494.
8. O'Connell RJ, Merritt TM, Malia JA, et al. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol. 2003;41:2153-2155.
9. Delaney KP, Branson BM, Uniyal A, et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis. 2011;52:257-263.
10. Piwowar-Manning E, Fogel JM, Laeyendecker O, et al. Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening. HIV Clin Trials. 2014;15:62-68.
11. Koblin BA, Mayer KH, Eshleman SH, et al. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV Prevention Trials Network (HPTN) 061. PLoS One. 2013;8: e70413.
12. Mayer KH, Wang L, Koblin B, et al. Concomitant socioeconomic, behavioral, and biological factors associated with the disproportionate HIV infection burden among Black men who have sex with men in 6 U.S. Cities. PLoS One. 2014;9:e87298.
13. Marzinke MA, Breaud A, Parsons TL, et al. The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. Clin Chim Acta. 2014;433:157-168.
14. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001;75:4999-5008.
15. Rhee SY, Liu T, Ravela J, et al. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother. 2004;48:3122-3126.
16. Goujard C, Chaix ML, Lambotte O, et al. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis. 2009;49:982-986.
17. Altfeld M, Addo MM, Rosenberg ES, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS. 2003;17:2581-2591.
18. Gao X, O'Brien TR, Welzel TM, et al. HLA-B alleles associate consistently with HIV heterosexual transmission, viral load, and progression to AIDS, but not susceptibility to infection. AIDS. 2010;24: 1835-1840.
19. Vaidya SA, Streeck H, Beckwith N, et al. Temporal effect of HLA-B∗57 on viral control during primary HIV-1 infection. Retrovirology. 2013;10: 139.
20. Martinez-Picado J, Martinez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 2008;134:104-123.
21. Fogel JM, Wang L, Parsons TL, et al. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013;208:1624-1628.
22. Marzinke MA, Clarke W, Wang L, et al. Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection. Clin Infect Dis. 2013;58:117-120.
23. Kahle EM, Kashuba A, Baeten JM, et al. Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study. J Acquir Immune Defic Syndr. 2014;65:e90-e94.